Interní Med. 2007; 9(11): 507-513

Nonhypoglycemic effects of oral antidiabetic medications

MUDr. Pavlína Piťhová1, prof. MUDr. Jindřiška Perušičová DrSc2, MUDr. Michala Pelikánová1, MUDr. Eva Žakovičová1, MUDr. Erik Hollay3
1 Interní klinika fakultní nemocnice Motol a 2. lékařské fakulty Univerzity Karlovy v Praze
2 I. Interní klinika 2. LF UK a FN Motol, Praha
3 Diabetologické centrum, Interní klinika 2. LF UK a FN Motol, Praha

Most of oral antidiabetics with respect to mechanism of its effect influence besides sacharide metabolism even risk factors of cardiovascular diseases and may have protective effect on function of pancreatic V-cells, may influence the inflammation and production of imflammatory cytokines, atherosclerosis and stability of atherosclerotic plaques, control of cell cycle, apoptosis and carcinogenesis. The article describes so called pleiotropic effect of thiazolindiones, metformin, acarbosis and sulfonylurea secretagogs.

Keywords: diabetes mellitus type 2, oral antidiabetics, pleiotropic effect

Published: January 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Piťhová P, Perušičová J, Pelikánová M, Žakovičová E, Hollay E. Nonhypoglycemic effects of oral antidiabetic medications. Interní Med. 2007;9(11):507-513.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bailey CJ. New drugs for the treatment of diabetes mellitus. In: Alberti MG (Ed.). International textbook of diabetes mellitus. John Wiley and Sons,1997: 865-881.
    2. Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs.1993; 46(6): 1025-1054. Go to original source... Go to PubMed...
    3. Bays H, Mandarino L, DeFronzo R. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator - activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463-478. Go to original source... Go to PubMed...
    4. Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. European Journal of Pharmacology 2006; 533(1): 101-109. Go to original source... Go to PubMed...
    5. Berstein LM. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett 2005; 224(2): 203-212. Go to original source... Go to PubMed...
    6. Cristello F, Cela V, Artin PG, et al. Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome. Gynecol Endocrinol 2005; 21(6): 340-352. Go to original source... Go to PubMed...
    7. DeJager J, Kooy A, Lehert P, et al. Effects of short-term fragment with metformin on endothelial function and inflammatory activity in type 2 diabetes mellitus. J Intern Med 2005; 257: 100-109. Go to original source... Go to PubMed...
    8. Derosa G, Gaddi AV. Differential effect of glimepiride and rosiglitazone on metabolic kontrol of type 2 diabetic patiens treated with metformin, Diabetes Obesity Metabolism, 2006; 8: 197-205. Go to original source... Go to PubMed...
    9. Detaille D, Guigas B, Chauvin C, et al. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 2005; 54: 2179-2187. Go to original source... Go to PubMed...
    10. Elte JWF, Bliklé JF. Thiazolidindiones for the treatment of type 2 diabetes. European Journal of Internal Medicine 2007; 18: 18-25. Go to original source... Go to PubMed...
    11. Garber AJ. Metformin and other biguanides: Pharmacology and therapeutic usage. In Int Textbook of Diabetes Mellitus, Third Edition, edited by DeFronzo RA, Feranini E, et al. John Wiley&Sons Ltd., 2004: 851-869. Go to original source...
    12. Grey A, Bolland M, Gamble G, et al. The peroxisome-proliferator-activated gamma agonists rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrin Metab 2007; 92: 1305-1310. Go to original source... Go to PubMed...
    13. Hanefeld M, Chiasson JL. Acarbose Slows Progression of Intima - Media Thickness of the Carotid Arteries in Subjects With IGT. Stroke 2004; 35(5): 1073-1078. Go to original source... Go to PubMed...
    14. Hawley SA, Boudeau J, et al. Complexes between the LKB1 tumor supressor, STRAD alpha/ beta and MO25 alpha/beta are upstrea kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2 (4): 28. Go to original source... Go to PubMed...
    15. Komers R, Vrána A. Thiazolidindiones - tools for the research of metabolic syndrom X. Physiol Res 1998; 47: 215-225.
    16. Langenfeld MR, Forst T, Hohnberg C, et al. Pioglitazone decreases carotid intima-media thickness independenty of glycemic control in patients with type 2 diabetes mellitus. Results from a controlled randomized study. Circulation 2005; 111: 2525-2531. Go to original source... Go to PubMed...
    17. Leclerc I, et al. Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab 2004; 286: E1023-E1031. Go to original source... Go to PubMed...
    18. Marchesini G, Marzocchi R et al. Non-alcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16 (4): 421-427. Go to original source... Go to PubMed...
    19. Meisner F, Walcher D, Gizard F, et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arterioscler Tromb Vasc Biol 2006; 26 (4): 845-850. Go to original source... Go to PubMed...
    20. Toshiba K, Nomada M, Efficacy of glimepiride on insulin resistence, adipocytokines and atherosclerosis, The Journal of Medical Investigation, 53, 2006. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.